Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Goodman SG, et al. Among authors: tan m. Circulation. 2003 Jan 21;107(2):238-44. doi: 10.1161/01.cir.0000050144.67910.13. Circulation. 2003. PMID: 12538422 Clinical Trial.
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; INTERACT Trial Long-Term Follow-Up Investigators. Fitchett DH, et al. Among authors: tan m. Am Heart J. 2006 Feb;151(2):373-9. doi: 10.1016/j.ahj.2005.05.003. Am Heart J. 2006. PMID: 16442903 Clinical Trial.
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Goodman SG, Bozovich GE, Tan M, Dos Santos A, Gurfinkel EP, Cohen M, Langer A; Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. Goodman SG, et al. Among authors: tan m. Am Heart J. 2006 Apr;151(4):791-7. doi: 10.1016/j.ahj.2005.08.007. Am Heart J. 2006. PMID: 16569535
7,230 results